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Abstract: Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and
mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding
of the pathogenesis of CFLD is key in order to develop efficacious treatments. However, it remains
complex, and has not been clarified to the last. The search for a drug might be additionally complicated
due to the diverse clinical picture and lack of a unified definition of CFLD. Although ursodeoxycholic
acid has been used for decades, its efficacy in CFLD is controversial, and the potential of Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) modulators and targeted gene therapy in
CFLD needs to be defined in the near future. This review focuses on the current knowledge on
treatment strategies for CFLD based on pathomechanistic viewpoints.
Keywords: cystic fibrosis-related liver disease; CFTR modulators; ursodeoxycholic acid; liver
transplantation
1. Introduction
Cystic Fibrosis-related liver disease (CFLD) represents one of multiple optional organ manifestations
of Cystic Fibrosis (CF), the most frequent fatal autosomal recessive disorder in Caucasians [1,2]. CF is a
monogenic disease resulting from mutations within the cystic fibrosis transmembrane conductance
regulator (CFTR) on chromosome 7 currently comprising >2000 different mutations [3].
CFTR encodes for a protein that is found i.a. in epithelial cells of lungs, sweat glands, pancreas,
intestine, and liver. It belongs to the family of ATP-binding cassette (ABC) transporters (CFTR is
alternately known as ABC subfamily C member 7 (ABCC7)) and functions as a cyclic adenosine
monophosphate (cAMP)-dependent chloride channel that may open on the cell surface of epithelial
cells. This chloride channel is necessary to maintain an alkaline pH and dilute fluid secretions [4] via a
passive Cl−/HCO3− anion exchange on exocrine epithelia along their electrochemical gradient [5,6].
Defects of CFTR may lead to dehydration of secretions and hyperviscous mucus, causing a multisystem
disease with major affections of the respiratory, gastrointestinal, and hepatobiliary tract.
2. Epidemiology and Clinical Presentation of CFLD
Advances in patient care including solid organ transplantation have led to a strong increase of life
expectancy in patients with CF with an estimated median survival of >50 years in patients born in the
UK in 2000 and thereafter [7]. The recent introduction of CFTR-directed therapies may further prolong
survival in the future.
Albeit lung disease remains the main cause of morbidity and mortality, the changing demographics
of CF necessitate an increased focus also on other organ manifestations such as CFLD, which has
become one of the leading causes of death among patients with CF [8].
However, the definition and diagnostic criteria of CFLD are subject to adjustments. In 1949
Pugsley and Spence first reported a case of liver cirrhosis in a 17-year old patient with CF [9]. Since then,
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knowledge has been gathered and refined over years. The definition of CFLD as suggested by
Debray et al. in 2011 comprises the presence of significant findings in at least two of the four categories,
i.e., physical examination (hepatomegaly and/or splenomegaly), liver function tests (elevated aspartate
amino transaminase (AST), alanine amino transaminase (ALT), and gamma glutamyl transferase (GGT)
at least at three consecutive determinations over 12 months after excluding other causes of liver disease),
ultrasonography (signs of parenchymal liver disease, bile duct dilatation, and/or portal hypertension),
and/or liver biopsy [10]. Recently, Koh et al. suggested a refined definition, considering an individual
to have CFLD if there is radiologic or histologic evidence of cirrhosis or diffuse liver disease, or a
positive finding is present in at least two of four categories, i.e., liver function tests, radiologic imaging,
vibration controlled transient elastography, and/or noninvasive fibrosis biomarkers [11]. According to
the latter definition of CFLD, also a higher amount of patients affected might be identified [11].
In summary, the clinical presentation of CFLD may include elevated liver enzymes, cholangiopathy,
hepatic steatosis, portal hypertension including esophageal varices in about 70%, as well as focal
fibrosis and focal cirrhosis [12]. Risk factors for CFLD comprise male sex, presence of severe mutations,
history of meconium ileus, exocrine pancreatic insufficiency, Pseudomonas aeruginosa, CF-related
diabetes, and carrying the SERPINA 1 Z Allele [13–16].
The prevalence of CFLD in children and adults ranges from 27 to 47%: In a longitudinal study by
Colombo et al. including 177 consecutive patients with CF (mainly children) at their first presentation
with a median follow up of 14 years, 27% of patients developed CFLD (incidence rate 1.8%) diagnosed
by either ultrasound or liver enzymes (steatosis not deemed as CFLD) [13]. Of these, 35% developed
liver cirrhosis (n = 17/177 = 9.6%, incidence rate 4.5% during a median period of 5 years after diagnosis of
CFLD). In another longitudinal study by Lamireau et al. including 241 children with CF, the prevalence
of CFLD (detected by ultrasound) was 41% after 12 years, and cirrhosis occurred in 7.9% (n = 19/241)
of patients at a median age of 10 years [14].
A study by Koh et al. investigated adult onset CFLD in a cohort of 36 patients without CFLD during
childhood, who were followed for up to 38 years (median follow-up 24.5 years) [11]. The prevalence of
CFLD was 47% at a median age of 36.6 years.
A further longitudinal population-based study by Toledano et al. analyzed data of 3417 children
and adults with CF from the UK CF-registry and showed that the prevalence of CFLD (defined by
elevated liver enzymes and/or abnormal liver ultrasound including steatosis) has increased during
2008 to 2013 [16]. Furthermore, mortality in patients with CFLD was more than doubled compared to
patients without. Of note, liver cirrhosis was diagnosed at a median age of 19 years.
Thus, one the one hand, childhood-onset CFLD may progress over time, on the other hand also
adulthood-onset CFLD may occur with higher age. Both observations may be a result of increased
life expectancy of patients with CF. Whether childhood-onset (genetic factors more important) and
adulthood-onset CFLD (environmental factors, secondary/tertiary causes more important) have the
same pathogenesis in common remains to be elucidated.
Eventually, the definition of CFLD is not unified and is subject to changes due to the changing
epidemiology as well as new discoveries that make diagnostic tools more sensitive and specific.
3. Pathogenesis of CFLD
The pathogenesis of CFLD is believed to be multifactorial and not clarified to the last [17].
Thinking of the whole clinical picture of CFLD that could be present, i.e., cholangiopathy, steatosis,
liver fibrosis, focal cirrhosis, and portal hypertension (without cirrhosis being a mandatory requirement),
we probably need to distinguish between primary, secondary, and tertiary causes that also might
influence each other.
Primary causes for liver alterations, such as genetic factors affecting bile acid homeostasis and
epithelial innate immunity of the bile ducts, secondary causes such as CF-related diabetes (CFRD),
exocrine pancreatic insufficiency, intestinal inflammation, changes in the gut microbiome, as well as
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tertiary causes such as antibiotics, immunosuppressive medication, and high fat diet might coin the
clinical presentation of CFLD.
CFTR mutations are classified as class I, II, III, IV, V, and VI depending on the underlying CFTR
defect. Class I mutations affect biosynthesis of CFTR and thereby lead to the absence of a functional CFTR
protein. Class II mutations (including the most common CFTR mutation deletion of a phenylalanine at
position 508 (F508del)) interfere with protein maturation, why CFTR comes up misfolded and causes a
CFTR trafficking defect. Class III mutations lead to a defective Cl-/HCO3−-channel regulation. Class IV
mutations cause a decreased Cl−/HCO3−-channel conductance, Class V mutations cause a reduced
synthesis of CFTR, and Class VI mutations lead to CFTR membrane stability [2].
CFTR genotype-phenotype correlations, however, are generally weak due to different mutation
penetrance in various organs. More severe mutations such as classes I, II, and III present with higher
morbidity and mortality and correlate well with pancreatic insufficiency (>95%), meconium ileus
(>20%), higher sweat chloride levels (≥60 mmol/L), younger age (<1 year) at diagnosis, and liver
disease (in 3–5%) [18].
In the liver, CFTR is expressed in the apical membrane of cholangiocytes, but not hepatocytes [19],
and constitutes a major determinant of bile secretion. Dysfunctional or lacking CFTR protein leads
to a disrupted Cl−– and HCO3− secretion, and thus a hyperviscous and more acidic bile (including
aberrant bile acid composition and increased concentration of toxic bile acids). The resulting ductular
biliary obstruction leads to local inflammation resulting in the picture of sclerosing cholangitis as well
as portal inflammation, which may cause a focal fibrosis in the first place, but later multilobular fibrosis
and cirrhosis. Furthermore, as recently described by Fiorotto et al., CFTR is additionally involved
in the control of biliary epithelial inflammation and permeability in a mouse model [20]. This is
facilitated by controlling the activation of the tyrosine kinase Src, a protooncogene, which in turn
regulates toll-like receptor 4 (TLR-4)—responses to gut-derived endotoxins. Additionally, aberrant
TLR-4 activation decreases the epithelial barrier function leading to a back-diffusion of toxic bile acids
again causing peribiliary inflammation and fibrosis [20]. Additionally, the same researchers recently
postulated an auto-inflammatory component in the pathogenesis of CFLD as a result of aberrant
activation of the innate immune system. This may be mediated via an increased basal NF-kB activation
found in human F508del cholangiocytes, which in turn actively secrete pro-inflammatory chemokines
known to attract neutrophils. Furthermore, F508del cholangiocytes showed increased responsiveness
to endotoxins, as well as Src kinase activation and toll-like receptor 4 (TLR4) phosphorylation leading
to local inflammation [21].
Additionally, not only CFTR defects may cause CFLD, but also the SERPINA-1Z–allele has been
identified as a modifier gene for the development of CFLD [15]. In patients carrying the Z-allele the
α1-antitrypsin variant accumulates in hepatocytes and cholangiocytes [22], which could lead to further
endoplasmatic reticulum stress and predispose cholangiocytes to injury of other causes [23]. A recent
in silico analysis identified further candidate modifier genes potentially involved in CFLD (i.e., Solute
carrier family 33 acetyl-coenzyme A transporter member 1 (SLC33A1), glycoprotein NMB (GPNMB),
neutrophil cytosolic Factor 2 (NCF2), RAS guanyl nucleotide-releasing protein 1 (RASGRP1), lectin
galactosidase-binding soluble 3 (LGALS3), and protein-tyrosine phosphatase nonreceptor-type 13
(PTPN13)) [24].
A clear definition of CFLD, as well as unraveling the pathomechanism that underlies the
evolution of CFLD, including the consideration of its clinical characteristics and severity determine the
development of efficacious treatments.
4. General Treatment Recommendations for CFLD
Treatment of CFLD should be in the hand of an experienced, multidisciplinary team [25]. It comprises
two major aspects, firstly, treating the underlying liver disease itself, and secondly, managing nutritional
therapy, as well as portal hypertension and decompensated cirrhosis, both possible results of the
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underlying liver disease. Liver transplantation may be the ultimate treatment in patients with end-stage
liver disease.
Treating the underlying liver disease to date mainly includes the administration of ursodeoxycholic
acid (UDCA). Current knowledge on UDCA in CFLD is described in Section 5. The potential of CFTR
modulators, gene therapy and future treatment options is described in Sections 6–8.
Nutritional therapy with regard to CFLD mainly aims at improving the nutritional status of the
patient by optimizing dietary intake of calories (especially protein), pancreatic enzyme replacement,
supplementation of fat-soluble vitamins A, D, E, K, and insulin treatment in patients with CFRD.
It may also include the correction of deficiencies of essential fatty acids, carnitine and choline since an
association with liver steatosis has been postulated [25,26].
The management of portal hypertension in CFLD (especially adulthood CFLD) includes endoscopic
screening for gastroesophageal varices and consecutive band ligation or sclerotherapy as primary or
secondary bleeding prophylaxis [27]. Unselective beta-blocker therapy with propranolol or carvedilol
might be used in order to prevent bleeding [27], but should be used with caution in patients with
reactive airway disease, since randomized controlled trials in patients with CF are currently lacking.
Other complications of portal hypertension such as ascites, spontaneous bacterial peritonitis and hepatic
encephalopathy should be treated according to current guidelines on patients with decompensated
liver cirrhosis [28]. However, it needs to be taken into account that portal hypertension in patients with
CFLD often occurs in the absence of liver cirrhosis and the presence of preserved liver function [29].
Non-cirrhotic portal hypertension in CFLD was found to be associated with portal branch venopathy
in small case series [30,31]. In these patients, transjugular intrahepatic portosystemic shut can be a
therapeutic option.
Unified criteria for the indication and timing of liver transplantation for CFLD have not been
established so far. However, in patients with CF, deterioration of nutritional status and pulmonary
function should be given special consideration [10]. Since the median survival time has been increasing,
liver transplantation for CFLD might become more frequent in the future.
5. Effects of Ursodeoxycholic Acid on CFLD
As according to the Best Practice Guidance for the Diagnosis and Management of CFLD,
UDCA should be commenced as soon as the diagnosis of CFLD has been made at a dose of 20 mg/kg
body weight (BW) in order “to delay the progression of the disease” [10].
However, although UDCA has been repeatedly investigated as treatment for CFLD since the
1990s [32,33], until now its efficacy in CFLD has remained controversial. Several small prospective
case series and larger retrospective registry data mainly could demonstrate a significant positive
effect on liver enzymes, however, randomized controlled trials assessing hard endpoints such as
improvement in liver histology, mortality or liver transplant free survival are still lacking but remain
crucial. Furthermore, the interpretation of the findings is frequently limited due to the lack of a
homogenous definition of CFLD and uniform assessment of liver disease severity. Table 1 summarizes
the current knowledge on UDCA in CFLD-treatment.
The lacking evidence is made obvious by a Chochrane review from 2017, which analyzed
the present evidence on UDCA in terms of improvement of liver function, risk reduction for the
development of chronic liver disease, and improvement in general outcomes in CF [34]. All randomized
controlled trials that applied UDCA for at least three months compared with placebo or no additional
treatment were considered. Of 12 identified trials only three trials comprising 118 participants dating
back to the 1990s were included [35,36], applying 10–20 mg/kg body weight of UDCA for up to
12 months. No significant effect of UDCA could be found, not at least also due to the fact that patient
numbers analyzed were very small, and length of treatment with UDCA might have been too short.
A more recent longitudinal cohort study by Toledano et al. (already mentioned above) investigating
>3000 patients reported a positive association of UDCA with prolonged overall survival in patients
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without cirrhosis (HR 0.50, 95% CI 0.36–0.69, p < 0.0001) in contrast to patients with cirrhotic disease
(HR 1.19, 95% CI 0.46–3.10, p = 0.71) [16], suggesting a positive effect in patients with mild CFLD.
In summary, although the use of UDCA in CFLD has become a standard treatment, the scientific
basis for this requires more reliable data especially for efficacy endpoints in middle-and long-term
use. Nevertheless, UDCA appears to be beneficial, especially when started early and against the
background of lacking therapeutic alternatives.
6. Effects of CFTR Modulators on CFLD
CFTR modulators are small molecules, which directly target CFTR and thereby partly restore
altered CFTR protein function. Their development has presented a breakthrough in the treatment of
CF, however, their effect on CFLD remains widely unclear.
Generally, we need to distinguish between CFTR potentiators and correctors, as well as
stabilizers, amplifiers and read-through agents, which may be given in supplement to the first
two. Potentiators keep the CFTR channel open so that chloride transport is ensured, correctors may
help to ensure correct CFTR protein folding so that CFTR is able to traffic to the cell surface and
remains there longer. In addition, stabilizers promote CFTR maturation and plasma membrane stability,
and thereby increase the half-life of the CFTR protein, amplifiers may increase the amount of CFTR
protein that is produced by the cell, and read-through agents may bypass premature termination
codons. Currently, only CFTR potentiators and correctors are readily available to patients.
The CFTR modulator which was developed first was ivacaftor (VX-770, Kalydeco®), a CFTR
potentiator. The small molecule treating the class III mutation G551D gained FDA approval in 2012.
Later it became apparent that it also works in other class III and IV mutations (gating, residual function,
splice and conduction mutations). The second medication which was approved by the FDA in 2015
was a CFTR modulator combination of ivacaftor with lumacaftor (VX-770/VX-809, Orkambi®) to treat
homozygous F508del mutation (protein processing mutation). However, its effect on improvement
of FEV1 and reduction of pulmonary exacerbations was only small to modest, probably also due to
antagonistic effects of VX-809 and VX-770. In February 2018 tezacaftor, another corrector, was approved
in combination with ivacaftor (VX-661/VX-770, Symdeko®) for patients with at least one F508del
mutation (protein processing, residual function, splice mutations), bearing the advantage of lesser side
effects and drug interactions than the combination of lumafactor/ivacaftor.
Ivacaftor, lumacaftor, and tezacaftor all are deemed as first generation CFTR modulators.
Although their development represented a breakthrough in the management of patients with CF,
treatment with the first generation CFTR modulators either cannot target frequent mutations, or their
efficacy is limited. This has highlighted the need for further drug evolution and led to the development
of the next generation CFTR corrector VX-445/ elexacaftor, which is able to correct an additional defect
in the formation of the F508del-CFTR protein. Hence, a drug was approved as a triple combination of
ivacaftor, tezacaftor, and elexacaftor (VX-770/Vx-661/VX-445, Trikafta™) by the FDA in October 2019.
Trikafta™ is approved for patients with at least one F508del mutation and, in contrast to its predecessors,
shows higher efficacy and is estimated to be able to treat about 90% of the CF population [50–52].
Table 2 presents an overview on approved CFTR modulators and their effects.
Further CFTR modulators currently are being tested in phase 1 or 2, such as the CFTR potentiators
VX-561 (deuterated ivacaftor) and ABBV-3067, the CFTR correctors ABBV–2222, and VX-121, the CFTR
amplifiers fPTI-428, and PTI-CH, and the read-through agent ELX-02 [53].
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Table 1. Ursodeoxycholic Acid as Treatment for Cystic Fibrosis-Related Liver Disease.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion
Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Cotting et al.
[32] 1990
Prospective
cohort study
without
comparison
group
8 18.0 62.5
- chronic cholestasis
manifested by raised
liver enzyme activities
over at least one year,
associated with
abnormal of liver size,
liver surface, and
homogeneity of the
parenchyma in US.
- absence of surgically
treatable obstruction as
a cause of cholestasis
shown by US or
hepatobiliary
scintigraphy with
99mTc labeled
N-(2,6-diethyl-3-iodo-
phenylcarbamoylmethyl)-
iminodiacetate, or both.
15–20 mg 6 none
decrease in AST
(p < 0.005) and
ALT (p < 0.001)
BW increase
(p < 0.0001)
increase in muscle
mass (p < 0.05)
Colombo et al.
[33] 1990
Prospective
cohort study
without
comparison
group
9 10.7 66.0
- presence of firm
hepatomegaly and
- persistent increase in
standard liver function
test values during a
2-year period
10–15 mg
(plus taurine 30
mg/kg BW)
6
minor
abdominal
discomfort
in one
patient
decrease in ALT
and GGT
(p < 0.01) and AP
(p < 0.05)
Colombo et al.
[37] 1992
Prospective
cohort study
without
comparison
group
13
(of these 9
patients
were already
included in
[24])
11.0 69.2
- presence of clinical,
biochemical and
abnormalities in US
15–20 mg 10 to 12 none
improvement in
canalicular
excretory function
and biliary
drainage
(hepatobiliary
scintigraphy with
99mTc-labeled
trimethyl-bromo-
iminodiacetic
acid)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Galabert et al.
[38] 1992
Prospective
cohort study
without
comparison
group
22 15.3 77.3
- existence of chronic
cholestasis assessed by a
persistent
(>1 year) and significant
increase (>2 upper
normal limit) of GGT,
ALP and 5′-nucleotidase
- presence of firm
hepatomegaly, and
- abnormal findings on US
(increased size,
nonhomogeneous
echogenicity, irregular
surface)
10–20 mg 12 none
decrease in ALT
(p < 0.002),
AST (p < 0.01),
GGT (p < 0.001),
AP (p < 0.001)
Colombo et
al. [39] 1992
Prospective
cohort study
without
comparison
group
9 11.8 77.8
- progressive liver disease
was documented over a
2-yr period in
all patients from clinical,
biochemical and
echographical
abnormalities
5, 10, and 15 mg
in a replicated
latin square
design for 2 mo,
followed by 20
mg for 2 mo
4
(2 mo plus 2
mo)
n.r.
biochemical
improvement in
serum liver
enzymes was
significantly
greater with
higher doses
O’Brien et al.
[40] 1996
Posthoc
analysis of
randomized
controlled trial
6 vs. 6
without
UDCA
n.r. n.r.
- hepatomegaly (liver
span in excess of 12 cm)
and splenomegaly or
both, confirmed by US
and
- abnormal liver
biochemistry (GGT >50
IU/l, 5′nucleotidase > 15
IU/I) or
- both for at least 6 mo
20 mg 6 n.r.
decrease in AST,
GGT, and
5′nucleosidase
(p < 0.05)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Colombo
et al. [35] 1996
Multicentre,
double-blind,
placebo-controlled
trial
55 13.8 70.9
- presence of
hepatomegaly, confirmed
by US (increased liver
size, nonhomogeneous
echogenic pattern, and
irregular surface), and the
presence of abnormal
liver biochemistries
(serum transaminases,
GGT) of at least 1 year’s
duration.
- presence of serum
transaminase and GGT
levels exceeding 1.5 times
the upper limit of normal
on at least three
determinations over the
year
15–20 mg
(+ 30 mg/kg BW
taurine)
UDCA + taurine
vs. UDCA +
placebo vs.
placebo +
taurine vs.
double placebo
12
transient
diarrhea,
mild and
transient
abdominal
pain
decrease in GGT
(p = 0.025)
Lepage et al.
[36] 1997
Randomized
double-blind
placebo-controlled
crossover
study
19 11.9 68.4
- abnormal findings on at
least two liver function
tests (ALT, AST, GGT)
and
- an abnormal finding on
US or liver biopsy or both
15 mg;
increased to 30
mg if less than
50% decrease of
ALT or AST or
both within 2
mo was
achieved
(UDCA vs
placebo)
6
(6 mo
placebo, 6
mo UDCA;
13 of 19 pts
followed for
25 mo)
none
decrease in ALT
(p < 0.01) and
GGT (p < 0.001)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Van de
Meeberg et al.
[41]
1997
Randomized
trial (low dose
vs. high dose
UDCA)
30 18.3 64.7
- disturbed liver
biochemistry and the
presence of abnormalities
in US or esophageal
varices on endoscopy at
two separate occasions at
least 3 mo apart
- two or more of the
following biochemical
variables > 1.5 the upper
normal limit: bilirubin,
AP, GGT, ALT, AST, or
- if one of these factors >
1.5 the upper normal limit
in combination with the
presence of splenomegaly
or esophageal varices
10 mg vs. 20 mg 12
severe
pruritus in 2
pts required
treatment
stopp
- decrease in ALT
(p < 0.02) and
GGT (p < 0.004)
- high dose UDCA
induces a better
response in liver
enzymes
Lindblad et
al. [42] 1998
Prospective
cohort study
without
comparison
group
10 17.6 60.0
- probable or proven
cirrhosis on liver biopsy,
including fibrosis with
extensive bridging and/or
signs of irregularities of
the intrahepatic bile ducts
at endoscopic retrograde
cholangiography
10–15 mg 24 none
- decrease in ALT
and AST (p < 0.05)
- decrease in GGT
only significant
after 12 (p < 0.05)
but not 24 mo
- decrease in
immunoglobuline
G (p < 0.01)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Colombo et
al. [43,44] 1999
Prospective
cohort study
without
comparison
group
36 10.0 69.4
- persistence of at least
two of the following
clinical, laboratory and
ultrasonographic signs
for more than 1 year:
hepatomegaly, elevated
levels of serum liver
enzymes (AST, ALT,
GGT), abnormalities in
US (hepatomegaly,
increased or
heterogeneous
echogenicity, nodularity,
irregular margins, or
splenomegaly).
- exclusion of other liver
diseases by evaluating
copper metabolism,
α1-antitrypsin, non-organ
specific autoantibodies
and serologic markers of
hepatitis B and C
infection
20mg 60.5 n.r.
- decrease in AST
and GGT (p ≤
0.0125)
- delayed
intestinal
visualization at
hepatobiliary
scintigraphy
predicts better
response to
UDCA
Nousia-Arvanitakis
et al. [35] 2001
Prospective
cohort study
without
comparison
group
7 n.r. n.r.
- pts with nodular biliary
cirrhosis:
hepatosplenomegaly,
abnormal liver function
tests, and micronodular,
multilobular
heterogeneous
hyperechogenicity of the
hepatic parenchyma in
US confirmed by
percutaneous liver biopsy
20mg 120 n.r.
- normalization of
ALT, AST and
GGT in all pts
- no effect on focal
biliary cirrhosis
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of CFLD/Inclusion
Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side
Effects
Relevant
Findings
Desmond
et al.
[45]
2007 Retrospectivecohort study 22 n.r. 63.0
- persistent (> 6 mo) and
significant (> ×2 upper normal
limit) AST, ALT and/or ALP
elevation and/or hepatobiliary
symptoms (pruritus, fatigue or
right upper quadrant pain)
- positive liver histology (focal
biliary cirrhosis or multilobular
cirrhosis), or at least two of the
following parameters on at least
two consecutive examinations
spanning a 1-year period: (i)
clinical hepatomegaly (liver span
412 cm in the midclavicular line),
confirmed by US; (ii) abnormal
serum liver enzyme levels,
consisting of elevation above the
upper normal limits of two of the
following: AST, ALT, GGT or AP;
and (iii) US abnormalities other
than hepatomegaly (i.e., increased,
heterogeneous echogenicity;
nodularity; irregular margins;
splenomegaly). Ultrasonographic
pattern of steatosis did not
represent a diagnostic criterion. At
both the paediatric hospital and
the adult hospital, patients were
screened for other causes of
abnormal liver enzyme levels (i.e.,
hepatitis A, B or C virus;
cytomegalovirus; Epstein–Barr
virus; alcohol; drugs; or toxins)
and were excluded if any of these
were present
10–15 mg
was titrated
upwards
according
to symptomatic
and/or
biochemical
response
(reduction in
liver enzymes to
< ×1.5 upper
normal
limit)
43.2
transient
pruritus
in 2 pts
- decrease in ALT
(p < 0.001), AST
(p = 0.005), GGT
(p = 0.021) and AP
(p < 0.001)
- improvement in
hepatobiliary
symptoms
including pruritus,
fatigue and right
upper quadrant
pain (p = 0.0003)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Siano et al.
[46] 2010
Retrospective
cohort study
26
(14 pts with
early vs. 12
pts with late
introduction
of UDCA
n.r. 50.0 vs.75.0
- clinical (hepatomegaly),
biochemical (increase of
at least two serum liver
enzyme levels above the
upper normal limit) or
abnormalities in US
(increased echogenicity,
no cirrhosis) recorded on
two consecutive
examinations within a
3-month period, in the
absence of other possible
causes
- US pattern of steatosis
did not represent a
selection criterion
15 mg 108 n.r.
lower prevalence
of CFLD in early
UDCA group (p <
0.05)
Kappler et al.
[47] 2012
Retrospective
case-control
study
98 vs. 98 age-
and
gender-matched
controls
without
CFLD vs. 9
historical
controls
with CFLD
14.8 57.1
- elevation of one or more
serum liver enzymes
(ALT, AST, GGT, GLDH)
> 1.5 upper normal limit
and persisting for > 6
months, or
- liver enlargement >2 cm
for > 6 mo
- other potential causes of
liver disease such as
alpha 1-antitrypsin
deficiency excluded
20 mg 86.4 n.r.
decrease in ALT,
AST, GGT, GLDH
(p < 0.001)
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Van der Feen
et al. [48] 2016
Retrospective
cohort study
32 vs. 73
patients
without
CFLD
10.3 62.5
- at least two of the
following conditions
were present:
hepatomegaly confirmed
by US, other
abnormalities of the liver
parenchyma on
ultrasound, e.g.,
heterogeneous
echogenicity and
persistently increased
liver enzymes (ASAT,
ALAT, GGT) with at least
two out of these three
being abnormal for at
least
12 mo
- persistently raised
transaminases only
- US examination
consistent with cirrhosis,
i.e., nodular aspect of the
liver and/or a clearly
irregular liver contour
and/or splenomegaly
15–20 mg 103.2 n.r.
- decrease of ALT
(p < 0.001), AST
(p < 0.01), and
GGT (p = 0.01)
- Decrease in liver
stiffness (p < 0.01)
in a subgroup of
patients
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Boelle et al.
[49] 2019
Retrospective
multicentre
cohort study
605 (of these
38% under
UDCA at the
age of 30)
vs. 2723
without
CFLD
17.9 56.5
- at least two of the
following characteristics
present: (1) abnormal
physical examination
(hepatomegaly and/or
splenomegaly); (2)
abnormalities of liver
function tests defined as
an increase of
transaminase (ALT and/or
AST) and/or GGT levels
above the upper normal
limits; (3) US evidence of
liver involvement
(heterogeneous
echogenicity, irregular
margins, or nodularity),
portal hypertension
(splenomegaly, increased
thickness of the lesser
omentum,
spontaneous splenorenal
anastomosis, large
collateral veins, or
ascites), or biliary
abnormalities (bile duct
dilatation)
- cirrhosis, diagnosed by
US, CT, and/or MRI,
and/or portal
hypertension
(splenomegaly,
hypersplenism (platelets
<150 G/L and white
blood cells <3 G/L),
and/or spontaneous
portosystemic shunts on
US) and/or esophageal
varices
n.r. n.r. n.r.
no evidence of a
change in mean
age at severe
CFLD onset with
UDCA treatment
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Table 1. Cont.
Author Year Study Design
Number of
Patients
with CFLD
Mean/Median
Age (y) % Male
Definition of
CFLD/Inclusion Criteria
UDCA Dosage
(per kg Body
Weight/Day)
Treatment
Duration
(in Months)
Side Effects RelevantFindings
Toledano et
al. [16] 2019
Retrospective
multicentre
cohort study
1749 on
UDCA vs.
1668 without
UDCA
21.3 58.6
- elevated liver enzymes
(ALT, AST, or GGT)
- abnormal (but
non-cirrhotic)
appearances in US
including steatosis
- evidence of cirrhosis
in US
- evidence of cirrhosis and
portal hypertension as
evidenced by the
presence of
splenomegaly, ascites or
gastro-oesophageal
varices
n.r. 48 n.r.
UDCA in
non-cirrhotic pts
associated with
prolonged overall
survival (HR0.50,
95% CI 0.36–0.69,
p < 0.0001), but
not in cirrhotic pts
(HR 1.19, 95% CI
0.46–3.10, p = 0.71)
ALT, alanine aminotransferase; AST, aspartate amino transferase; AP, alkaline phosphatase; BW, body weight; CT, computed tomography; GGT, gamma glutamyl transpeptidase; GLDH,
glutamate dehydrogenase; MRI, magnetic resonance imaging; n.r., not reported; pts, patients; UDCA, ursodeoxycholic acid; US, ultrasound; Tc; technecium.
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For all currently available CFTR modulators in clinics it is recommended to check for liver function
test abnormalities (transaminases and bilirubin) on a regular basis, which have been described in
about 5% to 15% of patients as a potential side effect of these drugs up to >8 time the upper limit of
normal [50,54,55]. However, there is also some evidence that CFTR modulators might have a beneficial
effect on the liver. Van de Peppel et al. described that treatment with Ivacaftor partially restored
disrupted FGF19-regulated bile acid homeostasis in 117 patients with CFTR gating mutations (partially
F508del heterozygoty) participating in the GOAL study, yet these findings did not correlate with
CFTR function in other organs, as measured by sweat chloride levels or pulmonary function [56].
Furthermore, mid- and long-term effects on liver function or histology remain unclear. Another study
by Gelzo and colleagues reported a beneficial effect of Lumacaftor/Ivacaftor on cholesterol metabolism,
enterohepatic flux and improvement of alkaline phosphatase in 40 patients with at least one F508del
mutation [57]. A small study including 20 patients with CF, of which nine received Lumacaftor/Ivacaftor,
the use of this CFTR modulator combination was associated with less hepatic steatosis as assessed
by magnetic resonance imaging proton density fat fraction [58]. In an in vitro study with human
derived pluripotent stem cells induced to cholangiocytes, Fiorotto et al. could show that the effect of
Lumacaftor/Ivacaftor to correct and potentiate F508del CFTR by a combination with the Src inhibitor
PP2 successfully restored fluid secretion to normal levels [21].
Ivacaftor was also hypothesized to be effective in restoring defective phosphatidylcholine secretion
in five mutations in the ATP-binding sites of ABCB4, three of which five have been identified as gating
mutations in CF (G551D, S1251N, and G1349D) in cell models supplemented by a three-dimensional
structural modeling [59].
Finally, Ivacaftor has also shown therapeutic potential in an in vitro model of progressive familial
intrahepatic cholestasis type 2 (PFIC2) caused by ABCB11 missense mutations affecting bile salt export
pump (BSEP): Ivacaftor treatment increased the taurocholate transport activity of mutated BSEP by
1.7-fold, reaching 95% of BSEP function [60].
Table 2. Effects of approved Cystic Fibrosis Transmembrane Conductance Regulator modulators on
Cystic Fibrosis organ manifestations.
CFTR
Modulator
Effect on
CFTR
Targeted CFTR
Mutation Effect on the Liver
Effect on other
Organ Systems References
ivacaftor
(VX-770) potentiator
G551D, G1244E,
G1349D, G178R,
G551S, S1251N,
S1255P, S549N und
S549R
Increase in ALT
(13.2%), AST (9.6%)
and bilirubin (2.4%) >
2x to > 8x ULN
Significant
improvement in
FEV1% after 24 and
48 weeks
Significant reduction
of pulmonary
exacerbations
Significant increase
in body weight
[54]
(adults)
Elevate of liver
function test > 8x ULN
(15%)
significant
improvement in
FEV1% after 24 and
48 weeks
significant reduction
of pulmonary
exacerbations,
significant increase
in body weight
[55]
(small
children)
rescue of
disease-causing
variations in
ATP-binding sites of
ABCB4 that cause
defects in
phosphatidylcholine
secretion relevant to
bile composition
[59]
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Table 2. Cont.
CFTR
Modulator
Effect on
CFTR
Targeted CFTR
Mutation Effect on the Liver
Effect on other
Organ Systems References
ivacaftor/
tezacaftor/
elexacaftor
(VX-770/Vx-661/
VX-445
potentiator/
corrector/
corrector
Hetero- and
homozygous F508del
Increased liver
enzymes (8%) and
bilirubin (3%) > 2x
ULN
Significant increase
in FEV1% through
day 29
[50]
restores FGF19
regulated bile acid
homeostasis
[56]
increase in small
intestinal pH [61]
increase in
Akkermansia,
decrease in intestinal
inflammation
[62]
ivacaftor/
lumacaftor
(VX-770/VX-809)
potentiator/
corrector
Homozygous
F508del
One patient
discontinued
treatment because of
abnormal liver
function tests (before
taking lumacaftor)
Significant
improvement in
FEV1% after 56 days
[63]
significantly lower
hepatic steatosis
measured by magnetic
resonance imaging
proton density fat
fraction
[58]
ivacaftor/
tezacaftor
(VX-770/VX-661)
potentiator/
corrector
Hetero- and
homozygous F508del
Elevation of
transaminases >3x
ULN (0.6%)
Elevation of bilirubin
>2x ULN (1.2%)
significant
improvement in
FEV1% after 56 days
[64]
Heterozygous
F508del
significant
improvement in
FEV1% after 8 weeks
[65]
increase in
aminotransferase
concentrations (12%)
>3x to >5x ULN
significant increase
in FEV1% through
week 4,
significant increase
in body weight
[52]
In summary, CFTR modulators show a certain therapeutic potential in CFLD, but there is still
a long way to go and we are just at the beginning. We need to learn more about the mechanisms
underlying hepatic toxicity as well as improvement of liver alterations by CFTR modulators in order
to select patients who may benefit. This evolution might be inhibited by the fact that there is no
clear association of CFLD with genetic mutations, and that a unified definition of CFLD based on its
pathomechanism and pathophysiology is currently lacking. Thus, to date the therapeutic response to
CFTR modulators seems unpredictable.
7. Effects of Gene Therapies on CFLD
In contrast to CFTR modulators, which partially restore CFTR protein function, CFTR targeting
gene therapies establish a new, correct version of the CFTR gene in order to produce normally
functioning CFTR protein. In contrast to CFTR modulators, gene therapy bears the advantage that
patients may be treated independently of the underlying CFTR mutation.
A randomized controlled trial (phase 2b) investigated a nebulized pGM169/GL67A gene–liposome
complex delivering plasmid DNA encoding the CFTR gene to the lungs and demonstrated a significant,
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but modest effect on FEV1% after 1 year of monthly application [66]. Notably, this non-integrating
gene therapy had no negative effect on liver enzymes. However, the improvement of lung function
was lower in comparison to those achieved with CFTR modulators, so that the substance did not reach
clinical application.
Another approach is to use messenger ribonucleic acid (mRNA)-based treatments, such as
MRT-5005, to deliver the correct mRNA to lung epithelial cells in order to produce functional CFTR
protein. Currently, a clinical phase1/2 trial (NCT03375047, RESTORE-CF) is underway.
Further possibilities evolve by the use of clustered regulatory interspaced short palindrome
repeats (CRISPR)/Cas9 to repair defective CFTR in vitro and in vivo [67–69], but have not been tested
in models of CFLD or humans so far.
8. Conclusions and Future Treatment Options
There has been tremendous effort and progress in the treatment of CF within the last years. Due to
the favorable epidemiologic evolution we have to face increasing numbers of patients suffering from
CFLD. However, to date, an efficient causative therapy is lacking.
Besides the evolution of CFTR modulators restoring CFTR protein function, substances creating
an additive effect, such as Src inhibitors targeting the TLR-4-mediated inflammatory processes at the
bile duct epithelium could be a future treatment option, but have not been investigated in humans.
Furthermore, molecules involved in CFTR ubiquitylation that function as regulators of CFTR stability
and degradation have been discussed as promising therapeutic targets [70]. Mesenchymal stromal
cells and induced pluripotent stem cells have been investigated in CF lung disease in vitro and in vivo,
but have not been investigated in CFLD so far [71]. Finally, antifibrotic substances such as Farnesoid X
Receptor (FXR) agonists, which target both the gut and the liver, and are centrally involved in bile acid
homeostasis might be interesting candidates in the treatment of CFLD, but have not been investigated
in this indication [72].
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Abbreviations
CF Cystic Fibrosis
CFLD Cystic Fibrosis-related liver disease
CFTR cystic fibrosis transmembrane conductance regulator
ABC ATP-binding cassette
ABCC7 ABC subfamily C member 7
AST aspartate amino transaminase
ALT alanine amino transaminase
GGT
CFRD
gamma glutamyl transferase
Cystic Fibrosis–related diabetes mellitus
TLR4 toll-like receptor 4
SLC33A1
Solute carrier family 33 acetyl-coenzyme A
transporter member 1
GPNMB glycoprotein NMB
NCF2 neutrophil cytosolic Factor 2
RASGRP1 RAS guanyl nucleotide-releasing protein 1
LGALS3 lectin galactosidase-binding soluble 3
PTPN13 protein-tyrosine phosphatase nonreceptor-type 13
UDCA ursodeoxycholic acid
BW body weight
FEV1 forced expiratory volume in one second
FXR Farnesoid X Receptor
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51. Middleton, P.G.; Mall, M.A.; Dřevínek, P.; Lands, L.C.; McKone, E.F.; Polineni, D.; Ramsey, B.W.;
Taylor-Cousar, J.L.; Tullis, E.; Vermeulen, F.; et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis
with a Single Phe508del Allele. N. Engl. J. Med. 2019, 381, 1809–1819. [CrossRef]
52. Heijerman, H.G.M.; McKone, E.F.; Downey, D.G.; Van Braeckel, E.; Rowe, S.M.; Tullis, E.; Mall, M.A.;
Welter, J.J.; Ramsey, B.W.; McKee, C.M.; et al. Efficacy and safety of the elexacaftor plus tezacaftor
plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation:
A double-blind, randomised, phase 3 trial. Lancet 2019, 394, 1940–1948. [CrossRef]
53. Chandra, A.; Garthwaite, C.; Stern, A.D. Characterizing the Drug Development Pipeline for Precision
Medicines. Available online: https://www.cff.org/Trials/pipeline (accessed on 18 September 2020).
54. Ramsey, B.W.; Davies, J.; McElvaney, N.G.; Tullis, E.; Bell, S.C.; Dřevínek, P.; Griese, M.; McKone, E.F.;
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